This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Meta-analysis

Jeffrey L. Jackson, MD, MPH; Robert Gibbons, MD; Gregg Meyer, MD, MSc; Lisa Inouye, MD, MPH

Arch Intern Med. 1997;157(8):909-912.

Abstract
Background
Herpes zoster is a common affliction in older patients, with up to 15% experiencing some residual pain in the distribution of the rash several months after healing. Despite numerous randomized clinical trials, the effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia remains uncertain because of conflicting results.

Methods
Meta-analysis of published randomized clinical trials on the use of acyclovir to prevent postherpetic neuralgia using the fixed-effects model of Peto.

Results
Thirty clinical trials of treatment with oral acyclovir in immunocompetent adults were identified. After excluding studies with duplicate data, suboptimal and topical dosing, non—placebo-controlled or nonrandomized designs, and those using intravenous acyclovir, 5 trials were found to be homogeneous and were combined for analysis. From these trials, the summary odds ratio for the incidence of "any pain" in the distribution of rash at 6 months in adults treated with acyclovir was 0.54 (95% confidence interval, 0.36-0.81).

Conclusion
Treatment of herpes zoster with 800 mg/d of oral acyclovir within 72 hours of rash onset may reduce the incidence of residual pain at 6 months by 46% in immunocompetent adults.

Arch Intern Med. 1997;157:909-912

Author Affiliations
From the Department of Medicine, Madigan Army Medical Center, Tacoma, Wash (Dr Jackson); the Department of Medicine, Walter Reed Army Medical Center, Washington, DC (Dr Gibbons); the Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Md (Dr Meyer); and the Department of Medicine, Portsmouth Naval Medical Center, Portsmouth, Va (Dr Inouye).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

66-Year-Old Man With Inarticulate Speech
Curtis and Vikram
Mayo Clin Proc. 2007;82:1562-1565.
FULL TEXT  

Herpes zoster
Wareham and Breuer
BMJ 2007;334:1211-1215.
FULL TEXT  

Risk factors for postherpetic neuralgia in patients with herpes zoster
Jung et al.
Neurology 2004;62:1545-1551.
ABSTRACT | FULL TEXT  

Treatment of herpes zoster and postherpetic neuralgia
Johnson and Dworkin
BMJ 2003;326:748-750.
FULL TEXT  

Herpes Zoster
Gnann and Whitley
NEJM 2002;347:340-346.
FULL TEXT  

Postherpetic neuralgia
Bowsher et al.
BMJ 2001;322:859-859.
FULL TEXT  

Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up
Helgason et al.
BMJ 2000;321:794-794.
ABSTRACT | FULL TEXT  

Review: early treatment of acute herpes zoster may prevent or shorten the duration of postherpetic neuralgia
Lancaster
Evid. Based Med. 2000;5:144-144.
FULL TEXT  

Oral acyclovir in acute cutaneous herpes zoster
Terry and Buttress
Emerg. Med. J. 2000;17:366-366.
FULL TEXT  

No alternative to antiviral drugs for acute herpes zoster.
Dworkin et al.
Anesth. Analg. 1999;89:1585-1586.
FULL TEXT  

Acyclovir Reduces Risk for Postherpetic Neuralgia
Journal Watch Dermatology 1997;1997:13-13.
FULL TEXT  

ACYCLOVIR REDUCES RISK FOR POSTHERPETIC NEURALGIA
JWatch General 1997;1997:1-1.
FULL TEXT